Daily Aspirin Not Neuroprotective in ASPREE Trial

Daily low-dose aspirin does not reduce the risk of dementia, mild cognitive impairment (MCI), or cognitive decline, according to a secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, published in Neurology.
Source: JAMA - Category: General Medicine Source Type: research